SAN FRANCISCO–(BUSINESS WIRE)–InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced that it has expanded its global presence with the opening of multiple new locations in Asia-Pacific and North America. The company’s new facilities include Mandaluyong, Philippines; Kuala Lumpur, Malaysia; Melbourne, Australia; and San Diego, California, adding a large footprint of state-of-the-art laboratories and office space for scaling up InterVenn’s software development, technical support, clinical research and business development.
“Our global expansion reflects the significant opportunity to apply glycoproteomics to improve clinical decision-making and translational research on a worldwide scale,” said Aldo Carrascoso, CEO of InterVenn Biosciences. “Our new offices and laboratory space will enable us to scale our operations, better connect with biomedical hubs, access local talent and serve different regions with localized resources.”
With facilities already established in San Francisco and Southeast Asia, InterVenn is building on its momentum since it was started with the mission that “no one should ever be blindsided by disease.” Each new location will play a key role in the increasing efforts to advance the company on its mission:
The company was co-founded by world-renowned scientist and Stanford professor Carolyn Bertozzi, PhD, highly respected innovator and UC Davis professor Carlito LeBrilla, PhD, and Aldo Carrascoso, an expert in AI/ML and blockchain. InterVenn has developed the world’s first technology platform to interrogate and decode the glycoproteome which will help accelerate the shift from the healthcare industry’s traditional focus on disease management to the new realm of preventive care and health management. The global expansion will support and help accelerate this development and position the company to serve customers with state-of-the-art capabilities.